Skip to main content
. 2022 Apr 27;28:1610315. doi: 10.3389/pore.2022.1610315

FIGURE 2.

FIGURE 2

Relapse-free survival (RFS) after liver metastasectomy of patients with rectal cancer according to neutrophil-to-lymphocyte ratio (NLR) (A,B) and systemic immune-inflammation index (SII) (C,D) and according to treatment: no treatment (A,C) or chemotherapy (±targeted treatment) before metastasectomy (B,D).